Peptides are everywhere right now. They appear in bodybuilding forums, longevity podcasts, skincare ads, and increasingly in mainstream health journalism.
Joe Rogan endorses them. Silicon Valley biohackers inject them. In February 2026, Robert F. Kennedy Jr., America's top health official, announced plans to allow 14 peptides to be prepared by licensed compounding pharmacies.
This article is not here to sell you on peptides, or to scare you away from them. It is here to explain what they are, where they came from, what the research actually shows, and how the United Kingdom currently regulates them.
What Is a Peptide?
At the most basic level, a peptide is a chain of amino acids — the same building blocks that make up proteins. The distinction is size: peptides are smaller than proteins, typically defined as chains of fewer than 50 amino acids. When chains grow longer, they become proteins.
Peptides are fundamental to human biology.
- Insulin — the hormone that regulates blood sugar and without which diabetics cannot survive — is a peptide.
- Oxytocin, the molecule associated with bonding and trust, is a peptide.
- So are many hormones, neurotransmitters, and signalling molecules that govern how your body functions minute to minute.
The term has, however, taken on a second, colloquial meaning in recent years. In wellness and performance communities, "peptides" has become a catch-all term for a range of unlicensed compounds — some of which are not technically peptides at all — that are sold online and promoted for effects ranging from muscle growth and fat loss to cognitive enhancement and accelerated healing.
It is worth keeping those two definitions clearly separate. The biology of peptides, in the strict sense, is well-established and important. The claims made for specific grey-market compounds are a very different matter.
A Brief History: From Laboratory to Locker Room
The Early Science (1900s–1950s)
The scientific study of peptides began in earnest in the early twentieth century. Emil Fischer, a German chemist, synthesised the first peptide in a laboratory in 1901, establishing that amino acids could be linked chemically in a controlled way. This laid the groundwork for understanding protein structure and, eventually, for the possibility of designing molecules that could mimic or influence biological processes.
The isolation of insulin in 1921 by Frederick Banting and Charles Best at the University of Toronto was a defining moment, not just for peptide science but for medicine as a whole. For the first time, a naturally occurring peptide had been identified, isolated, and used therapeutically. Diabetics who had been dying were given years, sometimes decades, of additional life.
Over the following decades, researchers identified dozens of biologically active peptides. Oxytocin was synthesised in 1953 by Vincent du Vigneaud, earning him the Nobel Prize in Chemistry. Vasopressin, which regulates water retention in the kidneys, was characterised around the same time. Adrenocorticotropic hormone (ACTH), which signals the adrenal glands to produce cortisol, was isolated and eventually synthesised.
By the mid-twentieth century, the pharmaceutical industry had recognised that peptides — because they interact so precisely with biological receptors — represented a potentially powerful class of drug. The challenge was delivery: peptides are fragile molecules that the digestive system breaks down rapidly, which is why insulin must be injected rather than swallowed.
The Steroid Era and Its Shadow (1950s–1990s)
While peptide science was advancing in academic laboratories, a parallel culture was developing in competitive sport. From the 1950s onwards, anabolic-androgenic steroids — synthetic derivatives of testosterone — began spreading through weightlifting, bodybuilding, and eventually most elite sport.
Human growth hormone (HGH) was an important bridge between the two worlds. First synthesised in the 1980s, HGH became a sought-after performance-enhancing substance alongside steroids. It also introduced a generation of users to the concept of peptide-based performance enhancement — and to the black market that supplied it.
GLP-1 and the Scientific Breakthrough (1980s–2010s)
While grey-market experimentation was growing, legitimate peptide science was producing results of genuine and lasting importance.
Glucagon-like peptide 1 (GLP-1) was discovered in 1983. It is a hormone produced in the gut that signals to the pancreas to release insulin and to the brain to reduce appetite. Decades of research followed, leading eventually to the development of semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) — GLP-1 receptor agonists that have transformed the treatment of type 2 diabetes and obesity.
The Online Marketplace Emerges (2010s–present)
The internet transformed the peptide landscape. Academic papers that previously circulated only among researchers became freely accessible. Online forums allowed users in different countries to pool observations, discuss dosing schedules, and speculate on combinations. Suppliers — many based in China — found they could reach customers globally with minimal friction.
By the mid-2020s, the market had expanded well beyond gyms. Longevity enthusiasts, biohackers, professionals seeking cognitive enhancement, and people dissatisfied with conventional medicine had all become significant customer segments. The "wellness" market was valued at $2 trillion globally in 2025.
The Research Landscape: What Studies Actually Exist
This is where clarity matters most, and where the gap between popular claims and scientific evidence is widest.
BPC-157
BPC-157 (Body Protection Compound 157) is among the most discussed peptides in online communities. It is promoted for wound healing, gut repair, tendon recovery, and anti-inflammatory effects.
The evidence base in humans is extremely thin. A 2025 narrative review published in Current Reviews in Musculoskeletal Medicine confirmed that only three pilot studies have examined BPC-157 in humans — covering intraarticular knee pain, interstitial cystitis, and intravenous safety. No adverse effects were reported in these small studies, but the authors were clear that "rigorous, large-scale trials are lacking." A 2025 systematic review in Orthopaedic Journal of Sports Medicine of 36 studies spanning 1993–2024 found that in the one human study available, 7 out of 12 people with chronic knee pain felt relief for over six months — a promising signal, but from a sample size far too small to draw firm conclusions.
The remainder of the research consists of cell studies (in vitro) and animal studies, predominantly in rats. Animal studies are not worthless — they establish biological plausibility and help researchers understand mechanisms. But they are a long way from clinical evidence. As a comprehensive 2025 review in Pharmaceuticals concluded, BPC-157 "has not been approved for use in standard medicine by the FDA and other global regulatory authorities due to the absence of sufficient and comprehensive clinical studies confirming its health benefits in humans."
According to specific research, one specific benefit of BPC-157 is its apparent ability to stop angiogenesis — the formation of new blood vessels. It is also a known stopper of tumour growth.
Cancers require blood supply to grow, and drugs that suppress angiogenesis are a standard part of some cancer treatments. Whether BPC-157's pro-angiogenic effects would encourage tumour growth in humans has not been studied in a controlled trial.
A 2025 pilot safety study reported no measurable adverse effects on heart, liver, kidney, or thyroid markers following intravenous infusion — a cautiously encouraging finding, but one limited by its small scale and short follow-up.
TB-500 (Thymosin Beta-4)
TB-500 is often combined with BPC-157 in what users call the "Wolverine stack." Thymosin beta-4 is a naturally occurring peptide involved in cell migration, wound healing, and tissue repair.
The animal research is more substantial than for BPC-157, and there is a plausible biological mechanism — TB-500 promotes actin polymerisation, which is fundamental to cell movement and tissue repair. Some early-phase human trials have taken place in specific medical contexts (cardiac repair following heart attack), but these are small and their results have not translated to approved treatments.
For general healing and recovery in healthy individuals, there are no controlled human trials.
Ipamorelin
Ipamorelin is a growth hormone secretagogue — it signals the pituitary gland to release more human growth hormone (HGH). It is promoted as a cleaner alternative to direct HGH supplementation because it stimulates natural release rather than introducing exogenous hormone.
Ipamorelin was originally developed by Novo Nordisk and has been studied extensively in animal models, where it has shown effects on bone mineral content, muscle composition, and post-surgical recovery. The distinction from direct HGH may matter less than enthusiasts suggest. The side effects of chronically elevated HGH include cardiomegaly (enlargement of the heart), an elevated risk of certain cancers, acromegaly (abnormal bone growth in the face, hands, and feet), and carpal tunnel syndrome. These are not theoretical concerns: they are documented consequences of HGH excess in humans.
Ipamorelin has not been approved for human use by any major regulatory body. It exists in clinical literature primarily as a research compound, and it is prohibited under the WADA Prohibited List adopted by UK Anti-Doping (UKAD).
PT-141 (Bremelanotide)
PT-141 is one of the more interesting cases because it has actually been through clinical trials and received regulatory approval — specifically, approval by the US Food and Drug Administration (FDA) for the treatment of hypoactive sexual desire disorder in pre-menopausal women.
This makes it unusual in the peptide landscape: there is a legitimate, approved, studied version of the compound. However, it is also sold online as part of what one clinic describes as an "Adonis protocol" for male sexual enhancement — a use for which it has not been approved and for which the evidence base is far weaker.
Retatrutide
Retatrutide is a triple hormone receptor agonist developed by Eli Lilly — it targets GLP-1, GIP, and glucagon receptors simultaneously. Early clinical trial data suggests it may produce even more significant weight loss than semaglutide.
It is still in clinical trials. It has not been approved by any regulator. It is nonetheless being sold online, and anecdotal reports suggest it is widely used. The risks of taking a compound still in trial — where the full safety profile is unknown — are considerable.
ACE-031
ACE-031 is a compound that targets myostatin, a protein that limits muscle growth. In theory, inhibiting myostatin would allow muscles to grow larger without additional training. Clinical trials were conducted by Acceleron Pharma, primarily in the context of Duchenne muscular dystrophy.
Those trials were halted in 2011 due to safety concerns, including nosebleeds, gum bleeds, and blood vessel dilation. A 2017 paper in Muscle & Nerve confirmed the study was stopped after the second dosing regimen due to epistaxis and telangiectasias (small dilated blood vessels). In May 2013, Acceleron and Shire formally discontinued the programme. The compound was shelved — yet it continues to circulate in the grey market.
The Quality Problem
Even setting aside the question of efficacy, there is a more fundamental issue with grey-market peptides: purity and contamination.
A comprehensive pharmacovigilance analysis drawing on published forensic studies found alarming patterns across grey-market peptide samples:
-
30% of online peptides contained incorrect amino acid sequences, meaning nearly one in three products did not contain the intended peptide structure.
-
65% exceeded safety thresholds for endotoxin contamination, bacterial byproducts that can trigger systemic inflammation or sepsis when injected
-
A Belgian forensic analysis found that 26% of seized injectable peptides had arsenic or lead exceeding pharmaceutical safety thresholds, with inorganic arsenic detected at up to ten times the permitted parenteral limit
A separate case reported by a US concierge physician illustrated the problem vividly: a patient brought in a vial of L-carnitine purchased online based on recommendations from "longevity people." When tested, it contained multiple unidentified compounds, including two synthetic stimulants with ecstasy-like properties, an agricultural weedkiller, and an industrial chemical.
The 99% HPLC purity figure that appears on many certificates of analysis is worth understanding precisely. HPLC measures the proportion of the target molecule relative to other peptide sequences.
It says nothing about non-peptide contaminants like residual solvents, heavy metals, or bacterial endotoxins.
A product can be 99% pure by HPLC and still contain dangerous levels of other substances.
When a compound is produced without regulatory oversight, the label provides no reliable information about what is actually in the vial.
UK Regulation: The Current Legal Position
The regulatory landscape in the United Kingdom is complex and, critics argue, inadequate to the scale of the market that has developed.
The Medicines and Healthcare products Regulatory Agency (MHRA)
The MHRA is the UK body responsible for regulating medicines and medical devices. Under the Human Medicines Regulations 2012, a substance must have a marketing authorisation (a licence) before it can be sold as a medicine for human use. Selling an unlicensed medicine for human consumption is a criminal offence.
Most grey-market peptides do not have marketing authorisations. Selling them as medicines for human use is therefore illegal in the UK.
The "Research Chemical" Loophole
The grey market operates through a legal mechanism that has become deeply familiar to anyone who has spent time in these communities. Peptides can be sold legally if they are labelled as "research chemicals" and explicitly stated to be not for human use.
This is not a secret loophole that sellers exploit reluctantly. It is the explicit and transparent basis on which the entire online peptide market operates. However, the MHRA's position is nuanced and important. As The Pharmacist reported following direct contact with MHRA Head of Borderlines Lynda Scammell, the agency takes the view that even "research use only" labelling does not automatically exempt a product from medicines legislation — what matters is intent and presentation. If the MHRA determines that a product is being sold with an implied medicinal purpose, it can classify it as an unlicensed medicine regardless of the label.
Critically, the General Pharmaceutical Council (GPhC) has written directly to pharmacists warning that products not licensed by the MHRA "are not required to meet good manufacturing practice, including safety, quality and efficacy standards."
MHRA Enforcement Action
The MHRA has been stepping up enforcement, though the scale of the market presents significant challenges. The agency has issued warnings about unlicensed GLP-1 products, conducted raids on manufacturing facilities, and shut down websites. In late 2025 and early 2026, two manufacturing sites suspected of producing illegal weight-loss drugs were closed.
The agency's challenge is jurisdictional as well as practical. Many suppliers are based outside the UK, primarily in China. Shutting down a UK-based website does not prevent a customer from ordering directly from an overseas supplier.
Anabolic Steroids and Class C
For context, anabolic steroids — the older generation of performance-enhancing compounds — are controlled substances in the UK under the Misuse of Drugs Act 1971 (Class C). Possession is not a criminal offence, but supply without a licence is. This creates an inconsistency: steroids, which have been in use for decades and whose effects are reasonably well characterised, are controlled; many peptides, which are newer and less understood, sit in a grey area that amounts to de facto legal availability.
Import Rules
Importing prescription-only medicines for personal use exists in a grey area. MHRA guidance states that small quantities imported for personal use may not be subject to enforcement action, but this is a discretionary position rather than a right. Importing controlled drugs is a different matter and carries criminal penalties.
Human Use vs. Research Use: What the Distinction Actually Means
The "research use only" framing that characterises the grey-market peptide industry deserves more scrutiny than it typically receives.
Genuine research chemicals are substances used in laboratory settings to investigate biological mechanisms. They are handled by trained scientists, in controlled conditions, following ethical protocols, with oversight from institutional review boards. When something goes wrong in a research setting, there is a chain of accountability and documentation.
When an individual purchases a peptide online, reconstitutes it at home, and injects it based on guidance from an internet forum, none of those conditions apply. The "research use only" label does not transform the activity into scientific research. It is a legal classification that has become detached from the reality of how these compounds are used.
The case of Bostin Loyd — an American bodybuilder who died in 2022 from a ruptured aorta after years of steroid and peptide use, and who had developed severe kidney failure that he attributed to adipotide — illustrates the risks that individual users carry alone.
Where the Science Needs to Go
The honest position is this: for most grey-market peptides, we do not know enough to make confident claims in either direction. The animal research is intriguing for several compounds. The mechanisms proposed are often biologically plausible. But biological plausibility is not clinical evidence, and the history of medicine is full of compounds that seemed promising in animal models and failed — or caused harm — in humans.
What is needed is straightforward: properly conducted human trials, with adequate sample sizes, control groups, pre-registered outcomes, independent oversight, and long enough follow-up to detect delayed adverse effects. As one 2025 narrative review concluded about BPC-157 — in language that applies equally to most compounds in this space — "there is a critical need for well-designed human trials to assess the safety, efficacy, and clinical utility" before any confident claims can be made.
Until that evidence exists, any claim about what a specific peptide will or will not do in a human body is, at best, informed speculation.
A Note on This Site
Regen Peptides supplies research-grade compounds for legitimate research purposes in compliance with UK law. Nothing on this site constitutes medical advice, and our products are not supplied for human consumption. If you are considering any intervention for health or performance purposes, consult a qualified medical professional who can assess your individual circumstances and access the most current clinical evidence.
The history of peptides is still being written. The most important chapters — the controlled human trials that will establish what these compounds can and cannot do — are yet to come.
BPC-157 narrative review, Current Reviews in Musculoskeletal Medicine (2025)
BPC-157 systematic review, Orthopaedic Journal of Sports Medicine (2025)
BPC-157 multifunctionality review, Pharmaceuticals (2025)
BPC-157 IV safety pilot, PubMed (2025)
Ipamorelin GH secretagogue research, PubMed
ACE-031 trial halt, Muscular Dystrophy Association
Grey-market peptide contamination analysis
MHRA/GPhC guidance via The Pharmacist
Human Medicines Regulations 2012